Back to Search
Start Over
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
- Source :
-
Breast cancer (Tokyo, Japan) [Breast Cancer] 2017 May; Vol. 24 (3), pp. 473-482. Date of Electronic Publication: 2016 Sep 15. - Publication Year :
- 2017
-
Abstract
- Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer.<br />Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed.<br />Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months.<br />Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
- Subjects :
- Breast Neoplasms metabolism
Breast Neoplasms therapy
Cohort Studies
Disease-Free Survival
Female
Humans
Middle Aged
Neoplasm Recurrence, Local metabolism
Neoplasm Recurrence, Local pathology
Prognosis
Receptor, ErbB-2 metabolism
Receptors, Estrogen metabolism
Breast Neoplasms mortality
Breast Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1880-4233
- Volume :
- 24
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Breast cancer (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 27628678
- Full Text :
- https://doi.org/10.1007/s12282-016-0730-3